Last update 01 Nov 2024
Shanghai Longyao Biotech Co., Ltd.
Last update 01 Nov 2024
Overview
Basic Info
Introduction Shanghai Longyao Biotech Co., Ltd. specializes in offering health management services that leverage biotechnological innovations such as tumor immune cell technology, stem cell technology, cell storage technology, and anti-aging technology. The company operates in various fields including technology development, consulting, transfer, and services related to biotechnology. Additionally, they engage in the import and export of goods and related technologies. Shanghai Longyao Biotech Co., Ltd. was established on September 16, 2013 and is situated in Shanghai, China. |
Tags
Neoplasms
Immune System Diseases
Digestive System Disorders
Autologous CAR-T
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
一项评价LY007细胞注射液治疗复发/难治性CD20阳性B细胞非霍奇金淋巴瘤的耐受性、安全性和有效性的开放、单臂I期临床研究
[Translation] An open-label, single-arm Phase I clinical study to evaluate the tolerability, safety and efficacy of LY007 cell injection in the treatment of relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
An Evaluation of LY007 Cell Injection for Recurrent/Refractory CD20 Was Positive Tolerability, Safety, and Efficacy of B-cell Non-Hodgkin Lymphoma in Open, Single-arm Stage I Clinical Research
An Evaluation of LY007 Cell Injection for Recurrent/Refractory CD20 Was Positive Tolerability, Safety, and Efficacy of B-cell Non-Hodgkin Lymphoma in Open, Single-arm Stage I Clinical Research
100 Clinical Results associated with Shanghai Longyao Biotech Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Shanghai Longyao Biotech Co., Ltd.
Login to view more data
100 Translational Medicine associated with Shanghai Longyao Biotech Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 04 Dec 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 1 Clinical
2
3
Other
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free